Eprenetapopt Completed Phase 1 Trials for Myeloid Malignancies Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT04214860APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies